Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Non-Current Debt: 2023-2024

Historic Non-Current Debt for Iovance Biotherapeutics (IOVA) over the last 2 years, with Dec 2024 value amounting to $1.0 million.

  • Iovance Biotherapeutics' Non-Current Debt changed negligibly% to $1.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.0 million, marking a year-over-year negligible change of negligibly%. This contributed to the annual value of $1.0 million for FY2024, which is negligibly% changed negligibly from last year.
  • As of FY2024, Iovance Biotherapeutics' Non-Current Debt stood at $1.0 million, which was down 0.00% from $1.0 million recorded in FY2023.
  • Iovance Biotherapeutics' 5-year Non-Current Debt high stood at $1.0 million for FY2023, and its period low was $1.0 million during FY2023.
  • Its 2-year average for Non-Current Debt is $1.0 million, with a median of $1.0 million in 2024.